Lineage Cell Therapeutics (LCTX) director awarded 125,000 stock options at $1.30
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Lineage Cell Therapeutics director Michael H. Mulroy received a grant of stock options representing 125,000 common shares. The options carry an exercise price of $1.30 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market purchase or sale.
The options will vest and become exercisable on the earlier of July 1, 2027 or the date of the company’s next annual shareholder meeting, subject to his continuous service with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Mulroy Michael H.
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 125,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 125,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 125,000 options
Exercise price: $1.30 per share
Expiration date: July 1, 2036
+2 more
5 metrics
Option grant size
125,000 options
Stock Option (Right to Buy) awarded to director
Exercise price
$1.30 per share
Option exercise price for underlying common shares
Expiration date
July 1, 2036
Option term ending
Underlying shares
125,000 shares
Common shares underlying the option grant
Vesting trigger date
July 1, 2027
Latest vesting date, or earlier at next annual meeting
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, grant, award, or other acquisition, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 1.3000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-07-01T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
vest and become exercisable financial
"Will vest and become exercisable on the earlier of July 1, 2027"
FAQ
What did Michael H. Mulroy acquire in the latest LCTX Form 4 filing?
Michael H. Mulroy received a grant of stock options for 125,000 Lineage Cell Therapeutics common shares. The options are a compensation-related award, not an open-market trade, and give him the right to buy shares at a fixed exercise price.
What is the exercise price of Michael H. Mulroy’s new LCTX stock options?
The newly granted stock options have an exercise price of $1.30 per Lineage Cell Therapeutics share. This price is the cost per share he must pay to exercise the options and acquire the underlying common stock in the future.
When do Michael H. Mulroy’s LCTX stock options vest?
The options will vest and become exercisable on the earlier of July 1, 2027 or the date of Lineage Cell Therapeutics’ next annual shareholder meeting. Vesting is conditioned on his continuous service with the company through that time.
Is the recent LCTX Form 4 a buy or sell transaction?
The Form 4 reflects an acquisition of derivative securities through a stock option grant, coded as a grant or award. It does not report any open-market buying or selling of Lineage Cell Therapeutics common shares by Michael H. Mulroy.